Evidence map›Paper›PMID 41774093›Full record

Trial reportStem cell reviews and reports2026

TransEndocardial Injection of Autologous Expanded CD34

Jérôme Roncalli, François Roubille, Philippe Henon, Pierre-Yves Marie, Gilles Montalescot, Deepak L Bhatt, Guillaume Trebuchet, Matthieu de Kalbermatten, Ibon Garitaonandia, David M Smadja

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02669810 (EXpanded CELL ENdocardiac Transplantation), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02669810 phase2completednot on this map

EXpanded CELL ENdocardiac Transplantation (EXCELLENT)

TypeinterventionalSponsorCellProtheraRan2016 to 2024Enrolled49ConditionsAcute Myocardial InfarctionArmsPROTHERACYTES, Standard Treatment for CHF post AMI
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jérôme RoncalliDepartment of Cardiology, Institute Cardiomet, Centre d'Investigations Cliniques Biotherapies 1436, INSERM I2MC 1297, Toulouse University Hospital, Toulouse, France.
François RoubilleCardiology Department, Montpellier University Hospital, Montpellier, France.
Philippe HenonCellProthera, Mulhouse, France.
Pierre-Yves MarieNuclear Medicine & Nancyclotep Experimental Platform, CHRU-Nancy, Université de Lorraine, Nancy, France.
Gilles MontalescotACTION group, Sorbonne University, Institute of Cardiology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France.
Deepak L BhattMount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Guillaume TrebuchetCellProthera, Mulhouse, France.
Matthieu de KalbermattenCellProthera, Mulhouse, France.
Ibon GaritaonandiaCellProthera, Mulhouse, France.
David M SmadjaParis Cité University, INSERM PARCC, UMR-S 970, Paris, France. david.smadja@me.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Percutaneous autologous expanded CD34⁺ cell therapy (ProtheraCytes

Indexed as

Antigens, CD34Myocardial InfarctionQuality of LifeStem Cell TransplantationAgedFemaleHumansMaleMiddle AgedTransplantation, AutologousTreatment OutcomeAntigens, CD34CD34+ cellsHealth-related quality of life (HRQoL)Myocardial infarctionProtheraCytes®Transendocardial injection

Identifiers

PMID41774093

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.